MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
3.635
-0.215
-5.58%
Pre Market: 3.900 +0.265 +7.29% 06:29 03/28 EDT
OPEN
3.830
PREV CLOSE
3.850
HIGH
3.880
LOW
3.530
VOLUME
8.78K
TURNOVER
0
52 WEEK HIGH
4.450
52 WEEK LOW
1.300
MARKET CAP
117.27M
P/E (TTM)
-1.0580
1D
5D
1M
3M
1Y
5Y
Cellectar Biosciences Q4 EPS $(0.40) Beats $(0.59) Estimate
Benzinga · 1d ago
Cellectar Biosciences GAAP EPS of -$3.11 misses by $0.28
Seeking Alpha · 1d ago
*Cellectar Biosciences 2023 Research and Development Expense About $28.2M >CLRB
Dow Jones · 1d ago
*Cellectar Biosciences 2023 Loss/Shr $3.11 >CLRB
Dow Jones · 1d ago
Press Release: Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update Management to host a conference call today at 8:30 am ET. Cellectar is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company announced positive data from its pivotal study of iopofosine I 131 in Waldenstrom's macroglobulinemia.
Dow Jones · 1d ago
Press Release: Cellectar Biosciences Reports -2-
This news release contains forward-looking statements. Drug discovery and development involve a high degree of risk. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties. Cellectar is the only company involved in the CLOVER WaM pivotal trial for iopofosine.
Dow Jones · 1d ago
Earnings Scheduled For March 27, 2024
Local Bounti is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. Companies Reporting Before The Bell include REE Automotive and Lands' End. The companies are expected to report earnings for their fourth quarter before the bell.
Benzinga · 1d ago
Cellectar Biosciences FY 2023 Earnings Preview
Cellectar Biosciences (NASDAQ:CLRB) is scheduled to announce FY earnings results on Wednesday, March 27th. The consensus EPS Estimate is -$2.83. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward.
Seeking Alpha · 1d ago
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on to develop PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. It is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.